By Dr Jia (Jenny) Liu

Conference Papers

Lemech CR; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua A; Yeo B; Cohen H; Bray C; Wang Y; Mo J; Harvey K; Zhang H; Ling Z; King N; Chal J; Ding J; Cioffi M; Maurer M; Hofmeister RJ; Getts D; Swarbrick A; Cosman R, 2025, '1342 First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors', BMJ, pp. a1583 - a1583, presented at Late-Breaking Abstracts, http://dx.doi.org/10.1136/jitc-2025-sitc2025.1342

Liu JJ; Kichenadasse G; Guerrero TCH; Calvo E; Gan HK; Markman B; Garcia VM; Symeonides SN; Meyer T; Mirallas O; Thistlethwaite F; Ottensmeier CHH; Pinato DJ; Giovannetti M; Green D; Hyland N; Joyce PI; McAlpine C; Palmer T; Lillie THW, 2025, '1561P EMITT-1: Final clinical, PK & PD data from dose escalation and selection of recommended dose for expansion cohorts in a phase I study of GRWD5769 (a first-in-class ERAP1i) in patients with solid malignancies', in Annals of Oncology, Elsevier, pp. s931 - s932, http://dx.doi.org/10.1016/j.annonc.2025.08.2191

Liu JJ; Tebbutt N; Price TJ; Alasady R; Hsu E; Shafren D; Zdanska O; Wong M, 2025, '882eP Phase I study of intratumoural (IT) IVX037, a novel CD55-targeted oncolytic RNA virus, in advanced microsatellite stable (MSS) colorectal cancer (CRC): Serum biomarkers, viral kinetics, and KRAS mutation analysis', in Annals of Oncology, Elsevier, pp. s584, http://dx.doi.org/10.1016/j.annonc.2025.08.1453

Yu X; Zhang J; Liu JJ; Yang J; Yue J; Sun Y; Pan Y; Sun ML; Qin Y; Shen L; Song R; Ruan J; Zhou A; Mou Y; Aghmesheh M; Morris M; Yu X; Zhao X; Chen M; Tazbirkova A, 2024, '132MO Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study', in Annals of Oncology, Elsevier, pp. s1456, http://dx.doi.org/10.1016/j.annonc.2024.10.158

Liu JJ; Yu X; Zhang J; Yang J; Yue J; Sun Y; Pan Y; Sun M; Qin Y; Shen L; Song R; Ruan J; Zhou A; Mou Y; Liu Z; Liu Z; Morris M; Aghmesheh M; Tazbirkova A; Zhou H, 2024, '396MO Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study', in Annals of Oncology, Elsevier, pp. s160, http://dx.doi.org/10.1016/j.annonc.2024.05.311

Liu JJ; He S; Butow P; Shaw J; McHardy CJ; Harris G; Serafimovska A; Butt Z; Beith JM, 2023, 'Implementation study of a novel brief clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 Implementation Study).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Liu J; Price T; Tebbutt N; Hsu E; Al-Asady R; Shafren DR; Croll N; Wong M, 2023, '649 Phase 1a open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer', BMJ, pp. a740 - a740, presented at Regular and Young Investigator Award Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.0649

Liu J; Bui KT; Serafimovska A; Kialy BE; Hui MN; Goodwin A; McNeil CM; Costa DSJ; Butow P; Beith JM, 2020, 'CIFeR: A novel Clinician-lead Intervention to address Fear of cancer Recurrence (FCR) in breast cancer survivors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020

Patil V; Sloane MA; Wong JW; Liu J; Ward RL; Hesson LB, 2013, 'Abstract 2983: Gene resilencing following decitabine therapy is initiated by nucleosome reoccupancy and is related to CpG island shore methylation.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2983 - 2983, http://dx.doi.org/10.1158/1538-7445.am2013-2983

Back to profile page